STAT+: ASCO showcased the payoff for new cancer medicines: longer lives
CHICAGO — Well, that’s a wrap. The biggest meeting in cancer research — and, really,…
Category: ASCO23
STAT+: Buoyed by cancer advances, new ASCO president also stresses honest prognosis
CHICAGO — As a busy weekend at the American Society of Clinical Oncology annual meeting…
STAT+: Novocure’s electric fields device prolongs survival in lung cancer, but doubts remain
CHICAGO — A medical device made by Novocure that creates electric fields in the lungs…
STAT+: The woman behind AstraZeneca’s cancer winning streak
CHICAGO — It was the kind of moment scientists who develop new medicines wait their…
STAT+: FDA oncology head wants advisory panels to keep voting on new drugs
CHICAGO — As commissioner of the Food and Drug Administration, Robert Califf has made clear…
STAT+: Gilead’s CAR-T therapy prolongs survival in key blood cancer trial
CHICAGO — Yescarta, the CAR-T therapy made by the Kite unit of Gilead Sciences, prolonged…
STAT+: Keytruda’s benefits, a breast cancer win, the ‘dom-zim doublet’: Weekend wrap-up from ASCO
CHICAGO — The annual meeting of the American Society of Clinical Oncology is back in…
STAT+: ‘Extraordinary’ survival data for lung cancer patients is seen as boost for AstraZeneca drug
CHICAGO – Giving the AstraZeneca drug Tagrisso to patients with non-small cell lung cancer who…
STAT+: Targeted drug greatly slows progression of a brain cancer
CHICAGO – An experimental drug dramatically slowed the growth of glioma, a type of brain…
STAT+: Immunogen drug prolongs survival of women with advanced ovarian cancer
CHICAGO — An antibody that delivers chemotherapy directly to tumor cells extended the lives of…
Cross-border ‘twinning programs’ may reduce survival disparities for childhood leukemia
A few miles can mean a life or death difference to children with cancer, if…
STAT+: Novartis drug reduces breast cancer recurrence, but experts may debate results
Kisqali, a breast cancer pill made by Novartis, reduced the risk of recurrence of the…